Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 1
1986 4
1987 4
1988 9
1989 8
1990 2
1991 1
1992 3
1993 2
1994 2
1995 6
1996 3
1997 7
1998 3
1999 4
2000 2
2001 2
2002 1
2003 3
2004 3
2005 10
2006 6
2007 5
2008 3
2009 2
2010 2
2011 2
2012 2
2013 2
2014 1
2015 3
2016 13
2017 5
2018 5
2019 7
2020 20
2021 22
2022 12
2023 10
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S, Portacci A, Campisi R, Buonamico E, Pelaia C, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Crimi N, Scichilone N, Pelaia G, Carpagnano GE, Crimi C. Nolasco S, et al. Among authors: crimi n. Front Immunol. 2023 Jun 30;14:1204444. doi: 10.3389/fimmu.2023.1204444. eCollection 2023. Front Immunol. 2023. PMID: 37457743 Free PMC article.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Bronchiectasis and asthma: a dangerous liaison?
Crimi C, Ferri S, Crimi N. Crimi C, et al. Among authors: crimi n. Curr Opin Allergy Clin Immunol. 2019 Feb;19(1):46-52. doi: 10.1097/ACI.0000000000000492. Curr Opin Allergy Clin Immunol. 2019. PMID: 30516546 Review.
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A, Campisi R, Buonamico E, Nolasco S, Pelaia C, Crimi N, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Scichilone N, Pelaia G, Crimi C, Carpagnano GE. Portacci A, et al. Among authors: crimi n. ERJ Open Res. 2023 Oct 30;9(5):00419-2023. doi: 10.1183/23120541.00419-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37908397 Free PMC article.
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Louis R, et al. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. doi: 10.1016/j.jaip.2023.03.009. Epub 2023 Mar 21. J Allergy Clin Immunol Pract. 2023. PMID: 36948488 Free article.
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study.
Crimi C, Nolasco S, Noto A, Maglio A, Quaranta VN, Di Bona D, Scioscia G, Papia F, Caiaffa MF, Calabrese C, D'Amato M, Pelaia C, Campisi R, Vitale C, Ciampo L, Dragonieri S, Minenna E, Massaro F, Gallotti L, Macchia L, Triggiani M, Scichilone N, Valenti G, Pelaia G, Foschino Barbaro MP, Carpagnano GE, Vatrella A, Crimi N; Southern Italy Network on Severe Asthma Therapy. Crimi C, et al. Among authors: crimi n. J Allergy Clin Immunol Pract. 2024 Dec;12(12):3315-3327. doi: 10.1016/j.jaip.2024.08.033. Epub 2024 Aug 27. J Allergy Clin Immunol Pract. 2024. PMID: 39197750 Free article.
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.
Pelaia C, Crimi C, Benfante A, Caiaffa MF, Campisi R, Candia C, Carpagnano GE, Carrieri I, D'Amato M, Detoraki A, Barbaro MPF, Lombardo N, Macchia L, Maglio A, Minenna E, Nolasco S, Paglino G, Papia F, Ricciardi L, Scichilone N, Scioscia G, Spadaro G, Tondo P, Uletta Lionetti S, Valenti G, Vatrella A, Crimi N, Pelaia G. Pelaia C, et al. Among authors: crimi n. Respirology. 2024 Oct;29(10):869-879. doi: 10.1111/resp.14767. Epub 2024 Jun 7. Respirology. 2024. PMID: 38847185 Free article.
Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.
Bongiorno MR, Crimi N, Corrao S, Allotta A, Arena A, Brusca I, Heffler E, Malara G, Milioto M, Pistone G, Porto M, Raia E, Valenti G. Bongiorno MR, et al. Among authors: crimi n. Ann Allergy Asthma Immunol. 2016 Dec;117(6):703-707. doi: 10.1016/j.anai.2016.08.006. Epub 2016 Oct 6. Ann Allergy Asthma Immunol. 2016. PMID: 27720581 Review. No abstract available.
191 results